The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.
Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.
Age 18 years or older.
Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1).
Eligible for curative intent therapy, with surgical resection of cancer planned.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.
None
Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors
Cohort
Prospective
blood and tissue samples
Diagnostic testroutine standard of care
blood and tissue samples
Other interventionRoutine standard of care
7
Treatment groupsSee each treatment group below.
Blood and tissue biospecimen registry
To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.
Click on the lead sponsor to view all of their trials.
